Duncan McHale - Nov 7, 2023 Form 4 Insider Report for Evelo Biosciences, Inc. (EVLO)

Role
Chief Medical Officer
Signature
/s/ Marella Thorell, Attorney-in-Fact for Duncan McHale
Stock symbol
EVLO
Transactions as of
Nov 7, 2023
Transactions value $
-$1,024
Form type
4
Date filed
11/8/2023, 08:32 PM
Previous filing
Nov 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EVLO Common Stock Options Exercise +6.5K +47.84% 20.1K Nov 7, 2023 Direct F1
transaction EVLO Common Stock Sale -$1.02K -3.1K -15.45% $0.33 17K Nov 8, 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EVLO Restricted Stock Units Options Exercise $0 -6.5K -50% $0.00 6.5K Nov 7, 2023 Common Stock 6.5K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
F2 The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction entered into by the Reporting Person, solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $0.32 to $0.34, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
F4 The RSUs vest in four (4) substantially equal quarterly installments following the February 07, 2023 grant date, such that all of the Restricted Stock Units will become vested on the first anniversary of the grant date, subject to the Reporting Person's continued service to the issuer on each such vesting date. These RSUs have no expiration date.